1临床资料患者1,女性,51岁。2009年确诊右侧乳腺癌,于2009年7月13日在外院行静脉输液港植入术,经输液港行6次多西他赛联合表柔比星(表阿霉素)新辅助化疗。2010年2月来我院就诊,经专家会诊,改用口服卡培他滨(希罗达)联合拉帕替尼治疗。按常规输液港维护,每4周1次,维护4次均无异常反应,于2010年6月17日行第5次维护时,回 1 clinical data patients 1, female, 51 years old. The right breast cancer was diagnosed in 2009 and was implanted in the IV venous port outside the hospital on July 13, 2009. Neoadjuvant chemotherapy with docetaxel and epirubicin (epirubicin) was performed 6 times in transfusion port. February 2010 to our hospital, the expert consultation, the switch to oral capecitabine (Xeloda) combined with lapatinib treatment. According to conventional infusion port maintenance, once every 4 weeks, no abnormalities were maintained for 4 times. On June 17, 2010, during the 5th maintenance,